The drug development pipeline involves several stages including in vitro assays, in vivo assays, and clinical trials. For candidate selection, it is important to consider that a compound will successfully pass through these stages. Using graph neural networks, we developed three subdivisional models to individually predict the capacity of a compound to enter in vivo testing, clinical trials, and market approval stages. Furthermore, we proposed a strategy combing both active learning and ensemble learning to improve the quality of the models. The models achieved satisfactory performance in the internal test datasets and four self-collected external test datasets. We also employed the models as a general index to make an evaluation on a widely known benchmark dataset DEKOIS 2.0, and surprisingly found a powerful ability on virtual screening tasks. Our model system (termed as miDruglikeness) provides a comprehensive drug-likeness prediction tool for drug discovery and development.
CITATION STYLE
Cai, C., Lin, H., Wang, H., Xu, Y., Ouyang, Q., Lai, L., & Pei, J. (2023). miDruglikeness: Subdivisional Drug-Likeness Prediction Models Using Active Ensemble Learning Strategies. Biomolecules, 13(1). https://doi.org/10.3390/biom13010029
Mendeley helps you to discover research relevant for your work.